High DLL3 expression was associated with prolonged survival in brain tumors, such as low-grade gliomas (HR, 0.61; 95% CI, 0.46–0.81; P < 0.001) and high-grade gliomas (HR, 0.85; 95% CI, 0.80–0.91; P < 0.001), as well as in kidney cancers (HR, 0.60; 95% CI, 0.47–0.75; P < 0.001) and thyroid carcinomas (HR, 0.72; 95% CI, 0.58–0.90; P = 0.004). Here, DLL3 is linked to thyroid gland carcinoma.